PBMC-Humanized Models for In Vivo I/O Studies

Characterization and Optimization of MiXeno™, PBMC-Humanized Mouse Tumor Models, for the Evaluation of the In Vivo Activity of Immunotherapeutics

Lan Zhang, Haochen Wu, Shanshan Qi, Lianqi Zhao, Fei Chen, Ying Jin, Juan Zhang, Meng Qiao, Xiaoyu An, Weibin Tan*, Xiaoyan Fu*, Qian Shi, and WenQing Yang

*Taicang Blood Center, Taicang, Suzhou, P.R. China

The recent rise in cancer immunotherapy research and drug approvals is providing promising treatment options for cancer patients, as well as new opportunities for translational scientists to identify and develop new classes of immunomodulatory agent.

This is increasing the demand for complex preclinical models which can be used to fully assess immuno-oncology agents and their many and varied interactions with the immune system, including models for the in vivo assessment of human-specific immunotherapeutics.

CrownBio has developed a platform of PBMC-humanized mouse tumor models, which have a broad spectrum of applications in immuno-oncology including the evaluation of human specific immunomodulatory drugs in vivo. This poster details the characterization and optimization of these models for a range of cancer types.

Read this Poster to Discover:

• That a total of 20 PBMC-humanized tumor models have been developed, with multiple inoculation protocols for administration of both immune and cancer cells selected for different immunotherapeutics.
• How a broad range of immunotherapeutics including mAbs, checkpoint inhibitors, BiTE^®, or NK mediated modulators can be evaluated in vivo using PBMC-humanized models.
• That, for specific models, treatment with anti-PD-1 mAb causes an increase in CD45+/CD3+, CD45+/CD8+, and CD45+/CD4+ cell populations, which is consistent with in vivo efficacy and appears to be donor dependent.

Download the Poster Now!